Cardiac adverse effects of H1-antihistamines

Revue Francaise d'Allergologie et d'Immunologie Clinique

Volumn 38, Issue 10, 1998, Pages 931-934

  Rankin, A C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiac arrhythmia; Drug interaction; H1 antihistamines

Indexed keywords

ASTEMIZOLE; ERYTHROMYCIN; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; LORATADINE; POTASSIUM CHANNEL; TERFENADINE;

ALLERGY; CARDIOTOXICITY; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HUMAN; LONG QT SYNDROME;

EID: 0032425938     PISSN: 03357457     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0335-7457(98)80166-4     Document Type: Conference Paper

References (20)

1. Craft T.M. Torsade de pointes after astemizole overdose BMJ 292 1986 660
2. Delpón E. Valenzuela C. Gay P. Franqueza L. Snyders D.J. Tamargo J. Block of human cardiac Kv 1.5 channels by loratadine : coltage-, time-, and use-dependent block at concentrations above therapeutic levels Cardiovas. Res. 35 1997 341 350
3. Hanrahan J.P. Choo P.W. Carlson W. Greineder D. Faich G. Platt R. Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenace organization Ann. Epidemiol. 5 1995 201 209
4. Honig P.K. Woosley R.L. Zamani K. Conner D.P. Cantilena L.R. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin Clin. Pharmacol. Ther. 52 1992 231 238
5. Honig P.K. Wortham D.C. Zamani K. Conner D.P. Mullin J.C. Cantilena L.R. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences JAMA 269 1993 1513 1518
6. Honig P.K. Wortham D.C. Lazarev A. Cantilena L.R. Grapefruit juice alters systemic bioavailability and cardiac repolarisation of terfenadine in poor metabolizers of terfernadine J. Clin. Pharmacol. 36 1996 345 351
7. Koh K.K. Rim M.S. Yoon J. Kim S.S. Torsade de pointes induced by terfenadine in a patient with long QT syndrome J. Electrocardiology 27 1994 343 346
8. Lindquist M. Edwards I.R. Risks of non-sedating antihistamines Lancet 349 1997 1322
9. Matthews D.R. Mc Nutt B. Okerholm R. Flicker M. Mc Bride G. Torsades de pointes occurring in association with terfenadine use JAMA 266 1991 2375 2376
10. Monahan B.P. Ferguson C.L. Killeavy E.S. Lloyd B.K. Troy J. Cantilena L.R. Torsades de pointes occurring in association with terfenadine use JAMA 264 1990 2788 2790
11. Nightingale S.L. FDA proposes to withdraw terfenadine approval JAMA 277 1997 370
12. Pratt C.M. Hertz R.P. Ellis B.E. Crowell S.P. Louv W. Moyé L. Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter anti-histamines, ibuprofen and clemastine Am. J. Cardiol. 73 1994 346 352
13. Pratt C.M. Ruberg S. Morganroth J. Mc Nutt B. Woodward J. Harris S. Dose-response relation between terfenadine (Seldane) and the QTc interval in the scalar electrocardogram : distinguishing a drug effect from spontaneous variability Am. Heart J. 131 1996 472 480
14. + channel cloned from human heart Mol. Pharmacol. 44 1993 1240 1245
15. 1-receptor antagonists astemizole and terfenadine compared with chlopheniramine and pyrilamine Circ. Res. 76 1995 110 119
16. Simons F.E.R. Kesselman M.S. Giddins N.G. Pelech A.N. Simons K.J. Astemizole-induced torsade de pointes Lancet 2 1988 624
17. Tan H.L. Hou C.J.Y. Lauer M.R. Sung R.J. Electrophysiologic mechanisms of the Long QT Interval Syndromes and Torsades de Pointes Ann. Intern. Med. 122 1995 701 714
18. Thompson D. Oster G. Use of terfenadine and contraindicated drugs JAMA 275 1996 1339 1341
19. Woosley R.L. Chen Y. Freiman J.P. Gillis R.A. Mechanisms of the cardiotoxic actions of terfenadine JAMA 269 1993 1532 1536
20. Woosley R.L. Cardiac actions of antihistamines Ann. Rev. Pharmacol. Toxicol. 36 1996 233 252